Ineffectiveness of Antiresorptive Agent Drug Holidays in Osteoporosis Patients for Treatment of Medication-Related Osteonecrosis of the Jaw: Consideration from Immunohistological Observation of Osteoclast Suppression and Treatment Outcomes

• Published in: International journal of environmental research and public health 2022-09, Vol.19 (17), p.10898
• Main Authors: Omori, Keisuke, Otsuru, Mitsunobu, Morishita, Kota, Hayashida, Saki, Suyama, Koki, Naruse, Tomofumi, Soutome, Sakiko, Umeda, Masahiro
• Format: Article
• Language: English
• Subjects: Antimicrobial agents; Bisphosphonate-Associated Osteonecrosis of the Jaw - drug therapy; Bone Density Conservation Agents - therapeutic use; Cathepsin K; Clinical outcomes; Creatinine; Diabetes; Diphosphonates - adverse effects; Drug withdrawal; Humans; Medical prognosis; Methods; Monoclonal antibodies; Multivariate analysis; Osteoclasts; Osteonecrosis; Osteoporosis; Osteoporosis - drug therapy; Patients; Regression analysis; Retrospective Studies; Surgery; Teeth; Tooth extractions; Treatment Outcome
• ISSN: 1660-4601; 1661-7827; 1660-4601
• DOI: 10.3390/ijerph191710898

In patients with osteoporosis receiving antiresorptive agents (ARs), it has been widely practiced to withdraw ARs for several months before tooth extraction and during treatment if medication-related osteonecrosis of the jaw (MRONJ) develops. This study examined the effects of drug holidays on recovery from osteoclast suppression and the treatment outcomes. The relationship between the period of the drug holidays and treatment outcomes was examined retrospectively in 166 osteoporosis patients with MRONJ who received ARs. Histological examinations using hematoxylin and eosin staining and cathepsin K stains were performed to observe the recovery from osteoclast suppression in 43 patients in whom living bone was observed in the resection margins of the surgical specimens. Three-month AR drug holidays were not significantly correlated with the treatment outcomes of the 139 patients who underwent surgical treatment and the 27 who underwent conservative treatment. Of the 43 patients who underwent histological investigations, 16 had drug holidays from 7 to 678 days. Osteoclast suppression was observed in almost all patients, except in one without a drug holiday and one with a 261-day drug holiday. These findings suggest that AR drug holidays for approximately 3 months neither recover osteoclast suppression nor affect treatment outcomes.